NanoViricides Claims NV-387 Could Be Key in Fighting Bird Flu Pandemic
NanoViricides Claims NV-387 Could Be Key in Fighting Bird Flu Pandemic
NanoViricides, Inc. (NYSE:NNVC) (the "Company"), says that its broad-spectrum antiviral drug candidate NV-387 is the best weapon to fight a potential bird flu pandemic because the mercurial H5N1 Influenza A virus would not be able to escape the drug.
NanoViricides, Inc. (紐交所:NNVC)（以下簡稱「公司」）表示，其廣譜抗病毒藥物候選NV-387是應對潛在禽流感大流行的最佳武器，因爲變化無常的H5N1流感A病毒無法逃避這種藥物。
"Despite all changes, the H5N1 Influenza A virus should remain susceptible to NV-387 because NV-387 mimics the very essential host-side feature that H5N1 continues to use even as it changes," said Anil R. Diwan, Ph.D., President and Executive Chairman of the Company, adding "This drug puts us in a great position to be able to fight a bird flu pandemic should it happen."
公司總裁兼執行主席Anil R. Diwan博士表示：「儘管發生了所有變化，H5N1流感A病毒應仍然對NV-387敏感，因爲NV-387模擬了H5N1在變化時仍繼續使用的非常關鍵的宿主特徵。」 他補充道：「如果發生禽流感大流行，這款藥物讓我們處於能夠有效抗擊疫情的良好位置。」
WHO has stated "Available virus sequences from human cases [of H5 infection] have shown some genetic markers that may reduce susceptibility to neuraminidase inhibitors (antiviral medicines such as oseltamivir) [NAIs] or endonuclease inhibitors (such as baloxavir marboxil) [PBIs]" in their updated public health assessment of recent Influenza A H5 infections, dated December 20, 2024
世衛組織在2024年12月20日的最新流感A H5感染公共衛生評估中指出：「來自人類病例的可用病毒序列[H5感染]顯示出一些遺傳標記，可能降低對神經氨酸酶抑制劑（如奧司他韋）[NAIs]或內切酶抑制劑（如巴洛沙韋）的敏感性。」
譯文內容由第三人軟體翻譯。